Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers
1 other identifier
observational
150
1 country
1
Brief Summary
Colorectal cancers account for 783,000 new cases and cause 437,000 deaths per year across the world. Diagnosis in the early stages improves survival rates. Up to now, these cancers are mostly diagnosed only at later stages of the disease's course through histoimmune staining and molecular biology processes on the tissues biopsied from the gastrointestinal system under invasive diagnostic procedures of colonoscopy. Oral fluid presents a large protein complexity and has been recently used as a diagnostic biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for the colorectal cancer can be advantageous as it contains gastrointestinal fluids, in addition to bacteria and bacteria lysate, which can also serve as a bio-markers' source for colorectal cancers. Proteomic technologies provide the tools needed to discover and identify disease-associated biomarkers. The aim of the present study is to identify salivary bio-markers in patients suffering from colorectal cancers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2012
CompletedFirst Posted
Study publicly available on registry
August 29, 2012
CompletedStudy Start
First participant enrolled
September 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2013
CompletedAugust 29, 2012
July 1, 2012
1 year
August 27, 2012
August 27, 2012
Conditions
Study Arms (2)
Control
Healthy adults above the age of 18 years
Study
Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
Interventions
Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
Eligibility Criteria
Patients identified with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
You may qualify if:
- Has not yet started treatment for the identified cancer
You may not qualify if:
- medically compromised patients
- congenital syndromes
- being treated with radiotherapy or chemotherapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hadassah Medical Organization
Jerusalem, Israel
Related Publications (1)
Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, Chia D, Wong DT. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology. 2010 Mar;138(3):949-57.e1-7. doi: 10.1053/j.gastro.2009.11.010. Epub 2009 Nov 18.
PMID: 19931263RESULT
Biospecimen
whole saliva
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Moti Moskovitz, DMD, PhD
Hadassah Medical Organization
- PRINCIPAL INVESTIGATOR
Eyal Shtayer, MD
Hadassah Medical Organization
- PRINCIPAL INVESTIGATOR
Avi Levin, MD
Hadassah Medical Organization
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 27, 2012
First Posted
August 29, 2012
Study Start
September 1, 2012
Primary Completion
September 1, 2013
Last Updated
August 29, 2012
Record last verified: 2012-07